Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial.
Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial.
复制标题
DOI：
10.1002/art.38314
复制
发表时间：
2014-04
期刊：
影响因子：
--
通讯作者：
Boudreau R
中科院分区：
文献类型：
--
作者：
Kwoh CK;Roemer FW;Hannon MJ;Moore CE;Jakicic JM;Guermazi A;Green SM;Evans RW;Boudreau R
通过使用3 T磁共振成像（MRI）评估膝关节结构性病变，确定口服氨基葡萄糖补充剂的短期疗效。本研究设计为随机、双盲、安慰剂对照试验。招募是通过大量邮件和宾夕法尼亚州西南部的关节炎登记处进行的。总共招募了201名单膝或双膝轻度至中度疼痛的参与者，定义为西安大略和麦克马斯特大学骨关节炎指数（WOMAC）疼痛评分>25和<100。在这些受试者中，69.2%的受试者至少有1个膝关节的Kellgren/Lawrence分级>2。参与者接受了24周的治疗，使用1，500 mg盐酸氨基葡萄糖饮料或安慰剂饮料。主要结局是根据经验证的评分系统（全器官MRI评分（蠕虫））评估的双膝3 T MRI软骨损伤恶化减少。次要结局包括所有膝关节骨髓病变（BML）评分的变化和尿II型胶原C末端交联端肽（CTX-II）排泄的变化。与对照组相比，葡萄糖胺治疗组24周内膝关节任何经WORM评分的亚区中软骨损伤降低可能性的校正比值比（OR）为0.938（95%置信区间[95% CI] 0.528，1.666）。与接受葡萄糖胺治疗的受试者相比，对照受试者在24周内的BML改善更多（校正OR 0.537，95% CI 0.291，0.990），但BML恶化无差异（校正OR 0.691，95% CI 0.410，1.166）。没有迹象表明葡萄糖胺治疗会降低尿CTX-II的排泄（β = −0.10，95% CI −0.21，0.002）。这项短期研究的结果没有提供结构性效益的证据（即，MRI形态学特征或尿CTX-II排泄的改善）。
To determine the short-term efficacy of oral glucosamine supplementation by evaluating structural lesions in the knee joints, as assessed using 3T magnetic resonance imaging (MRI). This study was designed as a randomized, double-blind, placebo-controlled trial. Recruitment was performed via mass mailings and an arthritis registry in southwestern Pennsylvania. In total, 201 participants with mild-to-moderate pain in one or both knees, as defined by a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score >25 and <100, were enrolled. Of these subjects, 69.2% had a Kellgren/Lawrence grade >2 in at least 1 knee. Participants received 24 weeks of treatment with 1,500 mg glucosamine hydrochloride in beverage form or a placebo beverage. The primary outcome was decreased worsening of cartilage damage on 3T MRI of both knees, assessed according to a validated scoring system, the Whole-Organ MRI Score (WORMS). Secondary outcomes included change in bone marrow lesion (BML) scores in all knees and change in excretion of urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II). The adjusted odds ratio (OR) for the likelihood of decreased cartilage damage over 24 weeks in any WORMS-scored subregion of the knee in the glucosamine treatment group compared to the control group was 0.938 (95% confidence interval [95% CI] 0.528, 1.666). Compared to subjects treated with glucosamine, control subjects showed more improvement in BMLs (adjusted OR 0.537, 95% CI 0.291, 0.990) but no difference in worsening BMLs (adjusted OR 0.691, 95% CI 0.410, 1.166) over 24 weeks. There was no indication that treatment with glucosamine decreased the excretion of urinary CTX-II (β = −0.10, 95% CI −0.21, 0.002). The results of this short-term study provide no evidence of structural benefits (i.e., improvements in MRI morphologic features or urinary CTX-II excretion) from glucosamine supplementation in individuals with chronic knee pain.
登录
查看更多内容
影响因子：
--
作者：
Lawrence, Reva C.;Felson, David T.;Wolfe, Frederick
通讯作者：
Wolfe, Frederick
服用氨基葡萄糖后，胶原酶诱导的小鼠骨关节炎的骨吸收和重塑。
影响因子：
4.9
作者：
Ivanovska N;Dimitrova P
通讯作者：
Dimitrova P
影响因子：
7
作者：
Kraus, V. B.;Burnett, B.;Todman, M.
通讯作者：
Todman, M.
影响因子：
--
作者：
Garnero, P;Ayral, X;Delmas, PD
通讯作者：
Delmas, PD
影响因子：
5
作者：
HEINEGAR.D;TIDERSTR.G
通讯作者：
TIDERSTR.G